$IMAX

IMAX box office surge drives Wedbush target hike

Wedbush raised its price target for IMAX Corp. to $60, citing record Q3 box office performance and strong financial projections. The firm expects $712M in global IMAX box office revenue, surpassing 2026 guidance. Wedbush forecasts Q3 revenue of $161M, EBITDA of $84M, and EPS of $0.98, all above consensus. Growth drivers include more IMAX titles, global expansion, and alternative content. IMAX is set to report Q3 results the week of October 26.

Original reporting
Published Oct 14, 2026, 7:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 7:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
IMAX box office surge drives Wedbush target hike — source image
Decision brief

The 30-second read

$IMAXBullishMed
01

Why it matters

The upgrade may attract short‑term buying ahead of the earnings release, but risk remains if actual results diverge.

02

Market read

Analyst target raise ahead of earnings provides a fresh catalyst for IMAX, offering a medium‑term trading opportunity.

03

What to watch

Potential supply‑chain constraints or slower rollout of alternative content could temper growth.

Relevance 7/10Novelty 7/10Timing: pre‑earnings week of Oct 26

Background

Wedbush analysts forecast record Q3 box‑office revenue for IMAX and higher margins, prompting the target increase.

Company-level read

Ticker impact

$IMAXBullishHigh confidence
Context

Wedbush raised its price target for IMAX to $60 from $54 and reiterated an Outperform rating ahead of the company's Q3 earnings report.

Expected impact

likely upward pressure as investors price in the higher target and improved margin expectations

Evidence & confidence

Target hikes are a direct catalyst that often precede short‑term buying, especially with the earnings window next week.

Market effects

Positive outlook may lift other premium‑content exhibitors and theater‑related stocks.

U.S. entertainment and media sector could see modest gains.

Limited to markets tracking IMAX and related cinema chains.

Counterpoint

If earnings miss expectations, the target raise could be premature and lead to a sell‑off.

Key entities

  • Wedbush Securities

    Equity research firm that raised IMAX's price target.

  • IMAX Corp

    Cinema technology and exhibition company.

Related articles

$IMAXHigh

Imax is a must for movie theaters, making the stock a buy, Morgan Stanley says

Morgan Stanley initiated coverage of Imax with an overweight rating and a $63 price target, suggesting 18% upside. The bank cites Imax's growing network, film slate, and box office revenue growth. Imax's box office is projected to reach $1.7 billion in 2028, up from $1.5 billion in 2026. The success of 'The Odyssey' highlights the value of Imax's technology and brand. 12 of 14 analysts rate Imax a buy or strong buy, and shares are up 21% over the past three months.

$AMCHighAI 8/10

AMC Spikes 7% as Refinancing Pushes Maturities From 2029 to 2031; Cinemark and IMAX Edge Higher

AMC Entertainment (AMC) shares rose 7% to $2.88 after announcing debt refinancing, pushing its nearest large maturity from 2029 to 2031. The move involves a private placement of first lien notes due 2031 and a cash tender offer for outstanding 2029 notes, funded by new debt facilities. Cinemark (CNK) and IMAX (IMAX) stocks also rose, but less significantly. AMC's refinancing aims to simplify its debt structure and extend maturities, though it does not reduce the total debt.

$IMAXMed

IMAX at Bank of America 2026 Media,Communications & Entertainment Conference: global surge

IMAX Corporation (IMAX) reported strong global growth at the Bank of America 2026 Media, Communications & Entertainment Conference. CEO Rich Gelfond highlighted record box office performance, international expansion, and new revenue streams. Current-quarter box office is on track to exceed $600 million, with significant contributions from international markets and local-language films. The company operates 1,800 theaters, with 500 in backlog, and aims to expand further. IMAX is also diversifying

$IMAXMed

Why IMAX Stock Climbed to a New All-Time High Today

IMAX stock reached a new all-time high on Monday, rising 3.89% to $54.79. The surge was driven by the record-breaking success of The Odyssey, which became the highest-grossing IMAX release. CEO Rich Gelfond expects this to be their best year. Analyst Steve Frankel predicts IMAX will exceed estimates in the second half of 2026, with shares potentially rising to $60. The company's Q2 2026 revenue grew 12% to $103 million, with adjusted earnings up 65% to $0.43 per share.

$IMAXMed

“The Odyssey” Demand Drives IMAX Shares Higher

IMAX reported Q2 2026 revenue of $103M (up 12% YoY) and EPS of $0.43 (up 65%), driven by strong demand for 'The Odyssey'. The stock has gained 42% YTD, with institutional inflows contributing to a 103.5% rise over the past year. IMAX shows strong sales and EPS growth rates of 11.7% and 18.7% respectively over three years, with EPS expected to rise 14% this year.